Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

  1. Miles, D.W.
  2. De Haas, S.L.
  3. Dirix, L.Y.
  4. Romieu, G.
  5. Chan, A.
  6. Pivot, X.
  7. Tomczak, P.
  8. Provencher, L.
  9. Cortés, J.
  10. Delmar, P.R.
  11. Scherer, S.J.
Revue:
British Journal of Cancer

ISSN: 0007-0920,  1532-1827

Année de publication: 2013

Volumen: 108

Número: 5

Pages: 1052-1060

Type: Article

DOI: 10.1038/BJC.2013.69 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus